Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln

Sept 5 (Reuters) - Novo Nordisk will pay $58.7 million to resolve claims that the drugmaker's sales staff downplayed the importance of a warning about cancer risks on its diabetes medication Victoza's label, the U.S. Justice Department said on Tuesday. (Reporting by Nate Raymond in Boston; Editing by Phil Berlowitz)